RY 171.23 -1.0746% SHOP 170.14 2.1432% TD 81.85 -0.7879% ENB 62.92 0.5594% BN 84.78 -1.8636% TRI 244.07 -0.9215% CNQ 44.44 1.6236% CP 111.16 2.0753% CNR 147.09 2.2595% BMO 140.35 -1.2315% BNS 72.0 -0.0971% CSU 4795.7002 -0.5041% CM 88.52 1.351% MFC 42.53 -0.3047% ATD 76.2 1.3163% NGT 62.42 -0.5893% TRP 66.63 1.0005% SU 55.02 0.5299% WCN 269.74 -1.0927% L 182.96 1.4416%
Last update at 2025-02-04T17:13:00Z
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -4.57088M | -5.23530M | -4.41106M | -5.59854M | -7.41391M |
| Minority interest | - | - | - | - | - |
| Net income | -4.57088M | -5.24847M | -4.41640M | -5.60822M | -7.42627M |
| Selling general administrative | 2.03M | 1.44M | 1.75M | 2.02M | 2.53M |
| Selling and marketing expenses | 0.10M | 0.09M | 0.10M | 0.45M | 0.72M |
| Gross profit | 0.31M | 0.63M | 0.31M | 0.27M | 0.06M |
| Reconciled depreciation | 0.29M | 0.31M | 0.28M | 0.27M | 0.26M |
| Ebit | -4.59426M | -5.20088M | -4.51888M | -5.59302M | -7.38652M |
| Ebitda | -4.30814M | -4.88765M | -4.24273M | -5.32074M | -7.13126M |
| Depreciation and amortization | 0.29M | 0.31M | 0.28M | 0.27M | 0.26M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -4.59426M | -5.20088M | -4.51888M | -5.59302M | -7.38652M |
| Other operating expenses | 5.66M | 6.37M | 5.32M | 6.63M | 8.38M |
| Interest expense | 0.03M | 0.02M | 0.00534M | 0.00968M | 0.01M |
| Tax provision | - | - | - | - | - |
| Interest income | 0.05M | 0.03M | 0.02M | 0.10M | 0.03M |
| Net interest income | 0.02M | 0.00941M | 0.02M | 0.09M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.00000M | 0.01M | 0.00534M | 0.00968M | 0.01M |
| Total revenue | 1.07M | 1.14M | 0.78M | 0.93M | 0.96M |
| Total operating expenses | 4.90M | 5.86M | 4.85M | 5.97M | 7.48M |
| Cost of revenue | 0.77M | 0.51M | 0.47M | 0.66M | 0.90M |
| Total other income expense net | 0.02M | -0.03442M | 0.11M | -0.00552M | -0.02740M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -4.57088M | -5.23530M | -4.41106M | -5.59854M | -7.41391M |
| Net income applicable to common shares | - | -5.23530M | -4.41106M | -5.59854M | -7.41391M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3.28M | 4.16M | 5.94M | 10.02M | 15.47M |
| Intangible assets | - | - | - | - | 0.00651M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.20M | - | 0.44M | 0.10M | 0.10M |
| Total liab | 1.37M | 1.07M | 0.87M | 0.86M | 1.61M |
| Total stockholder equity | 1.91M | 3.09M | 5.07M | 9.16M | 13.86M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.30M | 0.59M | - | 0.76M | - |
| Common stock | 46.44M | 44.53M | 42.12M | 42.12M | 42.12M |
| Capital stock | 46.44M | 44.53M | 42.12M | 42.12M | 42.12M |
| Retained earnings | -63.24000M | -58.45169M | -53.09230M | -48.50647M | -42.65215M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | 0.55M | 0.08M | 0.06M | 0.12M |
| Cash | 0.04M | 1.51M | 3.69M | 7.88M | 12.55M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1.08M | 0.68M | 0.87M | 0.82M | 1.52M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 0.34M | - | - | - | - |
| Short term debt | 0.09M | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.39M | - | - | - | - |
| Other stockholder equity | 12.49M | 5.64M | 5.10M | 5.30M | 7.40M |
| Property plant equipment | - | 1.11M | 0.87M | 1.04M | 1.15M |
| Total current assets | 1.50M | 2.50M | 5.00M | 8.92M | 14.19M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 3.09M | 5.07M | 9.16M | 13.85M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.60M | 0.44M | 0.30M | 0.49M | 0.82M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.66M | 0.49M | 0.57M | 0.45M | 0.72M |
| Accounts payable | 0.68M | 0.33M | 0.50M | 0.41M | 0.53M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 6.22M | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.92M | - | -0.00000M | - | 1.28M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.78M | 1.66M | 0.95M | 1.11M | 1.28M |
| Capital lease obligations | 0.39M | 0.47M | 0.04M | 0.09M | 0.14M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -0.03726M | -0.07041M | -0.10082M | -0.16458M | -0.53321M |
| Change to liabilities | - | -0.26561M | 0.07M | -0.71491M | 0.11M |
| Total cashflows from investing activities | - | -0.07041M | -0.10082M | -0.16458M | -0.53321M |
| Net borrowings | - | -0.04577M | -0.05662M | -0.05228M | -0.06023M |
| Total cash from financing activities | 2.65M | 3.02M | -0.05737M | -0.05756M | 18.61M |
| Change to operating activities | - | -0.22636M | -0.37614M | 0.05M | -0.02840M |
| Net income | -4.57088M | -5.23530M | -4.41106M | -5.59854M | -7.41391M |
| Change in cash | -1.46471M | -2.18304M | -4.18858M | -4.66831M | 11.51M |
| Begin period cash flow | 1.51M | 3.69M | 7.88M | 12.55M | 1.03M |
| End period cash flow | 0.04M | 1.51M | 3.69M | 7.88M | 12.55M |
| Total cash from operating activities | -4.07281M | -5.13287M | -4.03039M | -4.44617M | -6.56646M |
| Issuance of capital stock | 2.76M | 2.72M | 0.00000M | 1.60M | 17.48M |
| Depreciation | 0.29M | 0.31M | 0.28M | 0.27M | 0.26M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.17265M | 0.08M | -0.11395M | 0.27M | 0.14M |
| Change to account receivables | -0.02528M | -0.03119M | 0.23M | 0.39M | -0.03839M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 2.76M | 0.34M | -0.00075M | -0.00529M | 1.19M |
| Change to netincome | - | 0.24M | 0.34M | 0.93M | 0.42M |
| Capital expenditures | 0.04M | 0.07M | 0.10M | 0.16M | 0.53M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.43572M | -0.45187M | -0.23792M | -0.04964M | 0.17M |
| Stock based compensation | 0.62M | 0.19M | 0.32M | 0.91M | 0.39M |
| Other non cash items | 1.03M | 0.05M | 0.00534M | 0.00968M | 0.01M |
| Free cash flow | -4.11007M | -5.20329M | -4.13122M | -4.61074M | -7.09967M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLT Theralase Technologies Inc. |
-0.015 5.56% | 0.26 | - | - | 77.35 | 42.96 | 77.25 | -12.0585 |
| PINK Perimeter Medical Imaging AI Inc |
0.17 29.82% | 0.74 | - | - | 57.28 | 2.90 | 43.60 | -2.5521 |
| ASG Aurora Spine Corp |
-0.01 2.44% | 0.40 | - | - | 1.92 | 4.83 | 1.60 | 46.70 |
| VPT VentriPoint Diagnostics Ltd |
- -% | 0.10 | - | - | 320.99 | 7.13 | 333.50 | -6.6788 |
| NGMD NuGen Medical Devices Inc |
- -% | 0.07 | - | - | 56.50 | 9.71 | 79.77 | -4.5516 |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.
41 Hollinger Road, Toronto, ON, Canada, M4B 3G4
| Name | Title | Year Born |
|---|---|---|
| Dr. Arkady Mandel DSc., M.D., Ph.D. | Interim CEO, Chief Scientific Officer & Director | NA |
| Ms. Kristina Hachey CPA | CFO & Director | NA |
| Mr. David M. Groves B.A | Pres of World Trade Division | NA |
| Mr. Roger John Dumoulin-White | Director of Bus. Devel. | NA |
| Lori Leach | Marketing & Media Relations Consultant | NA |
| Mr. Vaughn Wyant | Marketing & Media Relations Consultant | NA |
| Dr. Terry Ruch DVM | Equine Medical Consultant | NA |
| Mr. Roger John Dumoulin-White B.Sc., P.Eng. | President, CEO & Director | NA |
| Dr. Arkady Mandel DSc., M.D., Ph.D. | Chief Scientific Officer & Director | NA |
| Mr. David M. Groves B.A | President of World Trade Division | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...